The BioPharma industry is in rapid flux, shaped by rising tariffs, shifting policies, and new barriers to prescription access. Here’s a quick look at the forces driving change.
Pharma Ad Rules Tighten—New Executive Order Triggers Immediate FDA Enforcement Actions
Source: Time.com
The time is now to review your campaigns as FDA oversight ramps up after years of minimal enforcement. Trump’s executive order triggers immediate FDA enforcement with AI-powered social media monitoring and hundreds of cease-and-desist letters sent. The administration is studying elimination of the 1997 “adequate provision” loophole, potentially requiring full side effect disclosure in all ads.
WHO Adds GLP-1 to Essential Medicines List—Causing High Demand, Prices, and Occasional Shortages
Source: PharmaExec
The World Health Organization has added GLP-1 medications for diabetes treatment to its essential medicines list. While these drugs are also widely used for weight loss, the designation applies only to their role in managing diabetes, where affordability and availability remain major challenges. WHO hopes this decision will drive broader access in low-income regions.
Point-of-Care Marketing Spending Passes $1B—Total Annual Revenues Climbed 16% Last Year
Source: FiercePharma
Spending on point-of-care (POC) drug marketing is surging, with revenues from the Point of Care Marketing Association (POCMA) members topping $1 billion last year—a 171% jump from 2019 to 2023, and an additional 16% jump from 2023 to 2024. Once seen as a secondary tactic, POC advertising is increasingly becoming the starting point for pharma campaigns, thanks to its ability to reach patients directly before consultations. Industry leaders from Pfizer and Bristol Myers Squibb praised the channel for delivering timely, impactful messaging that influences conversations between patients and healthcare providers.
